Cel-Sci Corporation, a Vienna-based company, is braving all odds to develop treatment for cancer, autoimmune, and infectious diseases. It is carrying out the R&D work of immunotherapy products to boost the immune system of patients.
Cel-Sci is a biotech company founded in 1983 by the founder, Maximilian de Clara. In 1970, he started working on producing products to boost the immune system to eradicate many severe diseases in humans.
However, many challenges on the path of R&D work made it difficult for the company to continue its work effectively. In the year 1978, Cel-Sci started researching Multikine at the Maz Plank Institute in Germany. Many obstacles such as funding issues, lack of technology, and the 2008 recession hindered the company’s work & growth.
Currently, Cel-Sci Corporation is investing in the research work of Multikine immunotherapy to treat cancer. Multikine helps to strengthen the immune system of the body to fight cancer cells naturally. Cel-Sci successfully completed Phase 1 and Phase 2 human trials with Multikine during 1994-2000.
Now, the biotech company is researching on its third phase trial and it is working to seek FDA approval for commercial distribution of Multikine. It is the dedicated efforts of the Cei-Sci team in the scientific research and management work that have made the biotech company reach this mark.
Multikine is a development immunotherapy product that is effective against HPV, HIV, Cervical Dysplasia, and head & neck cancer. L.E.A.P.S which stands for Ligand Epitope Antigen Presentation System is focusing on CEL-400 and LEAPS-H1N1-DC.
CEL-400 helps to treat rheumatoid arthritis and LEAPS-H1n1-Dc is a treatment for pandemic influenza. Both these products are currently under the development stage.
